RE: Modelling profits from the rapid LFT23 May 2020 18:03
@C - I think your low/med/high/cases are too extreme.
If you look at the profit per test to Avacta for your cases you are about $1, $5, and $13. So just on the profit per test your high low ratio is a factor of 13!
Below I have copied Kbiz post from 2nd May and he appears to have the right idea. You can adjust his numbers based upon recent news.
To try and get an accurate estimate price of the test I would guess it would lie between today's cost of a prego test and an HIV test which AS referenced in his webcast the other week. Thanks for your effort it deserved a reply.
Kbiz - copyright:
Taking another stab at the current valuation, and where this can go from COVID.
Assumptions:
- Fair value before COVID - £100m
- COVID testing requirements constant for 6 months minimum, 12 months maximum
- Successful vaccine eventually replace need for mass testing in 12 months
- Only adults tested
- 5% royalty for AVACTA - https://www.morse.law/news/setting-values-and-royalty-rates
- Additional market cap for covid = 2x 12 month earnings (based on the value of cash generated + derisking of future operations from this)
Variables:
- % of adult population tested
- % market share
- Cost per test
- Tests per adult
The case for £3:
- 7.7bn world population
- 3.85bn adults for testing
- 30% of adults regularly tested globally
- 1 test per week per adult = 26 tests min, 52 tests max
- Cost per test £2
- 10% market share
= £300m earning in 6 months or £600m in 12 months
Taking £300m earnings, x 2 = £600m + £100m pre-covid valuation = £700